APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Coccidioidomycosis Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Coccidioidomycosis Drug Market Analysis and Forecast 2026-2032

Report ID 173979140219 December 2025199 pages

Choose your research edition.

Industry ResearchCoccidioidomycosis Drug Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Coccidioidomycosis Drug Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Coccidioidomycosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Coccidioidomycosis Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Coccidioidomycosis Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Coccidioidomycosis Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Coccidioidomycosis Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Coccidioidomycosis Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Coccidioidomycosis Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Coccidioidomycosis Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Coccidioidomycosis Drug include Yi Kang Pharm, Teva Pharmaceuticals, ShiJiaZhuang No.4 Pharmaceutical, Qilu Pharmaceutical Group, Minsheng Pharmaceutical, Mylan, Lunan Pharmaceutical, Kelun and Pfizer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Coccidioidomycosis Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Coccidioidomycosis Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Coccidioidomycosis Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Coccidioidomycosis Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Coccidioidomycosis Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Coccidioidomycosis Drug revenue, projected growth trends, production technology, application and end-user industry.

Coccidioidomycosis Drug Segment by Company

Yi Kang Pharm

Teva Pharmaceuticals

ShiJiaZhuang No.4 Pharmaceutical

Qilu Pharmaceutical Group

Minsheng Pharmaceutical

Mylan

Lunan Pharmaceutical

Kelun

Pfizer

Bayer

Baxter

Sanofi-Aventis

Hexal

Apotex

Coccidioidomycosis Drug Segment by Type

Voriconazole

Fluconazole

Amphotericin B

Posaconazole

Others

Coccidioidomycosis Drug Segment by Application

Hospital

Retail

Others

Coccidioidomycosis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Coccidioidomycosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Coccidioidomycosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Coccidioidomycosis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Coccidioidomycosis Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Coccidioidomycosis Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Coccidioidomycosis Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Coccidioidomycosis Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Voriconazole Major Player Table 3. Fluconazole Major Player Table 4. Amphotericin B Major Player Table 5. Posaconazole Major Player Table 6. Others Major Player Table 7. Global Coccidioidomycosis Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospital Major Player Table 9. Retail Major Player Table 10. Others Major Player Table 11. Coccidioidomycosis Drug Industry Trends Table 12. Coccidioidomycosis Drug Industry Drivers Table 13. Coccidioidomycosis Drug Industry Opportunities and Challenges Table 14. Coccidioidomycosis Drug Industry Restraints Table 15. Global Coccidioidomycosis Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Coccidioidomycosis Drug Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Coccidioidomycosis Drug Market Share by Region (2021-2026) Table 18. Global Coccidioidomycosis Drug Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Coccidioidomycosis Drug Market Share by Region (2027-2032) Table 20. Global Coccidioidomycosis Drug Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Coccidioidomycosis Drug Revenue Market Share by Players (2021-2026) Table 22. Global Coccidioidomycosis Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Coccidioidomycosis Drug Key Players Headquarters & Area Served Table 24. Global Coccidioidomycosis Drug Players, Product Type & Application Table 25. Global Coccidioidomycosis Drug Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Coccidioidomycosis Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Coccidioidomycosis Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Coccidioidomycosis Drug Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Coccidioidomycosis Drug Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Coccidioidomycosis Drug Revenue Market Share by Type (2021-2026) Table 32. Global Coccidioidomycosis Drug Revenue Market Share by Type (2027-2032) Table 33. Global Coccidioidomycosis Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Coccidioidomycosis Drug Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Coccidioidomycosis Drug Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Coccidioidomycosis Drug Revenue Market Share by Application (2021-2026) Table 37. Global Coccidioidomycosis Drug Revenue Market Share by Application (2027-2032) Table 38. Yi Kang Pharm Company Information Table 39. Yi Kang Pharm Business Overview Table 40. Yi Kang Pharm Coccidioidomycosis Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Yi Kang Pharm Coccidioidomycosis Drug Product Portfolio Table 42. Yi Kang Pharm Recent Development Table 43. Teva Pharmaceuticals Company Information Table 44. Teva Pharmaceuticals Business Overview Table 45. Teva Pharmaceuticals Coccidioidomycosis Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Teva Pharmaceuticals Coccidioidomycosis Drug Product Portfolio Table 47. Teva Pharmaceuticals Recent Development Table 48. ShiJiaZhuang No.4 Pharmaceutical Company Information Table 49. ShiJiaZhuang No.4 Pharmaceutical Business Overview Table 50. ShiJiaZhuang No.4 Pharmaceutical Coccidioidomycosis Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. ShiJiaZhuang No.4 Pharmaceutical Coccidioidomycosis Drug Product Portfolio Table 52. ShiJiaZhuang No.4 Pharmaceutical Recent Development Table 53. Qilu Pharmaceutical Group Company Information Table 54. Qilu Pharmaceutical Group Business Overview Table 55. Qilu Pharmaceutical Group Coccidioidomycosis Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Qilu Pharmaceutical Group Coccidioidomycosis Drug Product Portfolio Table 57. Qilu Pharmaceutical Group Recent Development Table 58. Minsheng Pharmaceutical Company Information Table 59. Minsheng Pharmaceutical Business Overview Table 60. Minsheng Pharmaceutical Coccidioidomycosis Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Minsheng Pharmaceutical Coccidioidomycosis Drug Product Portfolio Table 62. Minsheng Pharmaceutical Recent Development Table 63. Mylan Company Information Table 64. Mylan Business Overview Table 65. Mylan Coccidioidomycosis Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Mylan Coccidioidomycosis Drug Product Portfolio Table 67. Mylan Recent Development Table 68. Lunan Pharmaceutical Company Information Table 69. Lunan Pharmaceutical Business Overview Table 70. Lunan Pharmaceutical Coccidioidomycosis Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Lunan Pharmaceutical Coccidioidomycosis Drug Product Portfolio Table 72. Lunan Pharmaceutical Recent Development Table 73. Kelun Company Information Table 74. Kelun Business Overview Table 75. Kelun Coccidioidomycosis Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Kelun Coccidioidomycosis Drug Product Portfolio Table 77. Kelun Recent Development Table 78. Pfizer Company Information Table 79. Pfizer Business Overview Table 80. Pfizer Coccidioidomycosis Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Pfizer Coccidioidomycosis Drug Product Portfolio Table 82. Pfizer Recent Development Table 83. Bayer Company Information Table 84. Bayer Business Overview Table 85. Bayer Coccidioidomycosis Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Bayer Coccidioidomycosis Drug Product Portfolio Table 87. Bayer Recent Development Table 88. Baxter Company Information Table 89. Baxter Business Overview Table 90. Baxter Coccidioidomycosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Baxter Coccidioidomycosis Drug Product Portfolio Table 92. Baxter Recent Development Table 93. Sanofi-Aventis Company Information Table 94. Sanofi-Aventis Business Overview Table 95. Sanofi-Aventis Coccidioidomycosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Sanofi-Aventis Coccidioidomycosis Drug Product Portfolio Table 97. Sanofi-Aventis Recent Development Table 98. Hexal Company Information Table 99. Hexal Business Overview Table 100. Hexal Coccidioidomycosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Hexal Coccidioidomycosis Drug Product Portfolio Table 102. Hexal Recent Development Table 103. Apotex Company Information Table 104. Apotex Business Overview Table 105. Apotex Coccidioidomycosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Apotex Coccidioidomycosis Drug Product Portfolio Table 107. Apotex Recent Development Table 108. North America Coccidioidomycosis Drug Revenue by Type (2021-2026) & (US$ Million) Table 109. North America Coccidioidomycosis Drug Revenue by Type (2027-2032) & (US$ Million) Table 110. North America Coccidioidomycosis Drug Revenue by Application (2021-2026) & (US$ Million) Table 111. North America Coccidioidomycosis Drug Revenue by Application (2027-2032) & (US$ Million) Table 112. North America Coccidioidomycosis Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 113. North America Coccidioidomycosis Drug Revenue by Country (2021-2026) & (US$ Million) Table 114. North America Coccidioidomycosis Drug Revenue by Country (US$ Million) & (2027-2032) Table 115. Europe Coccidioidomycosis Drug Revenue by Type (2021-2026) & (US$ Million) Table 116. Europe Coccidioidomycosis Drug Revenue by Type (2027-2032) & (US$ Million) Table 117. Europe Coccidioidomycosis Drug Revenue by Application (2021-2026) & (US$ Million) Table 118. Europe Coccidioidomycosis Drug Revenue by Application (2027-2032) & (US$ Million) Table 119. Europe Coccidioidomycosis Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. Europe Coccidioidomycosis Drug Revenue by Country (2021-2026) & (US$ Million) Table 121. Europe Coccidioidomycosis Drug Revenue by Country (US$ Million) & (2027-2032) Table 122. China Coccidioidomycosis Drug Revenue by Type (2021-2026) & (US$ Million) Table 123. China Coccidioidomycosis Drug Revenue by Type (2027-2032) & (US$ Million) Table 124. China Coccidioidomycosis Drug Revenue by Application (2021-2026) & (US$ Million) Table 125. China Coccidioidomycosis Drug Revenue by Application (2027-2032) & (US$ Million) Table 126. Asia Coccidioidomycosis Drug Revenue by Type (2021-2026) & (US$ Million) Table 127. Asia Coccidioidomycosis Drug Revenue by Type (2027-2032) & (US$ Million) Table 128. Asia Coccidioidomycosis Drug Revenue by Application (2021-2026) & (US$ Million) Table 129. Asia Coccidioidomycosis Drug Revenue by Application (2027-2032) & (US$ Million) Table 130. Asia Coccidioidomycosis Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 131. Asia Coccidioidomycosis Drug Revenue by Region (US$ Million) & (2021-2026) Table 132. Asia Coccidioidomycosis Drug Revenue by Region (US$ Million) & (2027-2032) Table 133. SAMEA Coccidioidomycosis Drug Revenue by Type (2021-2026) & (US$ Million) Table 134. SAMEA Coccidioidomycosis Drug Revenue by Type (2027-2032) & (US$ Million) Table 135. SAMEA Coccidioidomycosis Drug Revenue by Application (2021-2026) & (US$ Million) Table 136. SAMEA Coccidioidomycosis Drug Revenue by Application (2027-2032) & (US$ Million) Table 137. SAMEA Coccidioidomycosis Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 138. SAMEA Coccidioidomycosis Drug Revenue by Country (2021-2026) & (US$ Million) Table 139. SAMEA Coccidioidomycosis Drug Revenue by Country (US$ Million) & (2027-2032) Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. Coccidioidomycosis Drug Image Figure 2. Global Coccidioidomycosis Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Coccidioidomycosis Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Voriconazole Image Figure 5. Fluconazole Image Figure 6. Amphotericin B Image Figure 7. Posaconazole Image Figure 8. Others Image Figure 9. Global Coccidioidomycosis Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Coccidioidomycosis Drug Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospital Image Figure 12. Retail Image Figure 13. Others Image Figure 14. Global Coccidioidomycosis Drug Market Size (US$ Million) & (2021-2032) Figure 15. Global Coccidioidomycosis Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Coccidioidomycosis Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Coccidioidomycosis Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Coccidioidomycosis Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Coccidioidomycosis Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Coccidioidomycosis Drug Revenue Market Share by Type (2021-2032) Figure 22. Global Coccidioidomycosis Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Coccidioidomycosis Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Coccidioidomycosis Drug Revenue Market Share by Application (2021-2032) Figure 25. North America Coccidioidomycosis Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Coccidioidomycosis Drug Revenue Share by Type (2021-2032) Figure 27. North America Coccidioidomycosis Drug Revenue Share by Application (2021-2032) Figure 28. North America Coccidioidomycosis Drug Revenue Share by Country (2021-2032) Figure 29. United States Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Coccidioidomycosis Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Coccidioidomycosis Drug Revenue Share by Type (2021-2032) Figure 34. Europe Coccidioidomycosis Drug Revenue Share by Application (2021-2032) Figure 35. Europe Coccidioidomycosis Drug Revenue Share by Country (2021-2032) Figure 36. Germany Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Coccidioidomycosis Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Coccidioidomycosis Drug Revenue Share by Type (2021-2032) Figure 46. China Coccidioidomycosis Drug Revenue Share by Application (2021-2032) Figure 47. Asia Coccidioidomycosis Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Coccidioidomycosis Drug Revenue Share by Type (2021-2032) Figure 49. Asia Coccidioidomycosis Drug Revenue Share by Application (2021-2032) Figure 50. Asia Coccidioidomycosis Drug Revenue Share by Region (2021-2032) Figure 51. Japan Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Coccidioidomycosis Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Coccidioidomycosis Drug Revenue Share by Type (2021-2032) Figure 59. SAMEA Coccidioidomycosis Drug Revenue Share by Application (2021-2032) Figure 60. SAMEA Coccidioidomycosis Drug Revenue Share by Country (2021-2032) Figure 61. Brazil Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Coccidioidomycosis Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Voriconazole
  • Fluconazole
  • Amphotericin B
  • Posaconazole
  • Others
Applications
  • Hospital
  • Retail
  • Others
Companies covered
  • Yi Kang Pharm
  • Teva Pharmaceuticals
  • ShiJiaZhuang No.4 Pharmaceutical
  • Qilu Pharmaceutical Group
  • Minsheng Pharmaceutical
  • Mylan
  • Lunan Pharmaceutical
  • Kelun
  • Pfizer
  • Bayer
  • Baxter
  • Sanofi-Aventis
  • Hexal
  • Apotex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Coccidioidomycosis Drug Market by Type
  3. 1.2.1 Global Coccidioidomycosis Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Voriconazole
  5. 1.2.3 Fluconazole
  6. 1.2.4 Amphotericin B
  7. 1.2.5 Posaconazole
  8. 1.2.6 Others
  9. 1.3 Coccidioidomycosis Drug Market by Application
  10. 1.3.1 Global Coccidioidomycosis Drug Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospital
  12. 1.3.3 Retail
  13. 1.3.4 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Coccidioidomycosis Drug Market Dynamics
  1. 2.1 Coccidioidomycosis Drug Industry Trends
  2. 2.2 Coccidioidomycosis Drug Industry Drivers
  3. 2.3 Coccidioidomycosis Drug Industry Opportunities and Challenges
  4. 2.4 Coccidioidomycosis Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Coccidioidomycosis Drug Market Perspective (2021-2032)
  2. 3.2 Global Coccidioidomycosis Drug Growth Trends by Region
  3. 3.2.1 Global Coccidioidomycosis Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Coccidioidomycosis Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Coccidioidomycosis Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Coccidioidomycosis Drug Revenue by Players
  2. 4.1.1 Global Coccidioidomycosis Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Coccidioidomycosis Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Coccidioidomycosis Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Coccidioidomycosis Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Coccidioidomycosis Drug Key Players Headquarters & Area Served
  7. 4.4 Global Coccidioidomycosis Drug Players, Product Type & Application
  8. 4.5 Global Coccidioidomycosis Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Coccidioidomycosis Drug Market CR5 and HHI
  11. 4.6.3 2025 Coccidioidomycosis Drug Tier 1, Tier 2, and Tier 3
5 Coccidioidomycosis Drug Market Size by Type
  1. 5.1 Global Coccidioidomycosis Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Coccidioidomycosis Drug Revenue by Type (2021-2032)
  3. 5.3 Global Coccidioidomycosis Drug Revenue Market Share by Type (2021-2032)
6 Coccidioidomycosis Drug Market Size by Application
  1. 6.1 Global Coccidioidomycosis Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Coccidioidomycosis Drug Revenue by Application (2021-2032)
  3. 6.3 Global Coccidioidomycosis Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Yi Kang Pharm
  2. 7.1.1 Yi Kang Pharm Company Information
  3. 7.1.2 Yi Kang Pharm Business Overview
  4. 7.1.3 Yi Kang Pharm Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Yi Kang Pharm Coccidioidomycosis Drug Product Portfolio
  6. 7.1.5 Yi Kang Pharm Recent Developments
  7. 7.2 Teva Pharmaceuticals
  8. 7.2.1 Teva Pharmaceuticals Company Information
  9. 7.2.2 Teva Pharmaceuticals Business Overview
  10. 7.2.3 Teva Pharmaceuticals Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Teva Pharmaceuticals Coccidioidomycosis Drug Product Portfolio
  12. 7.2.5 Teva Pharmaceuticals Recent Developments
  13. 7.3 ShiJiaZhuang No.4 Pharmaceutical
  14. 7.3.1 ShiJiaZhuang No.4 Pharmaceutical Company Information
  15. 7.3.2 ShiJiaZhuang No.4 Pharmaceutical Business Overview
  16. 7.3.3 ShiJiaZhuang No.4 Pharmaceutical Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 ShiJiaZhuang No.4 Pharmaceutical Coccidioidomycosis Drug Product Portfolio
  18. 7.3.5 ShiJiaZhuang No.4 Pharmaceutical Recent Developments
  19. 7.4 Qilu Pharmaceutical Group
  20. 7.4.1 Qilu Pharmaceutical Group Company Information
  21. 7.4.2 Qilu Pharmaceutical Group Business Overview
  22. 7.4.3 Qilu Pharmaceutical Group Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Qilu Pharmaceutical Group Coccidioidomycosis Drug Product Portfolio
  24. 7.4.5 Qilu Pharmaceutical Group Recent Developments
  25. 7.5 Minsheng Pharmaceutical
  26. 7.5.1 Minsheng Pharmaceutical Company Information
  27. 7.5.2 Minsheng Pharmaceutical Business Overview
  28. 7.5.3 Minsheng Pharmaceutical Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Minsheng Pharmaceutical Coccidioidomycosis Drug Product Portfolio
  30. 7.5.5 Minsheng Pharmaceutical Recent Developments
  31. 7.6 Mylan
  32. 7.6.1 Mylan Company Information
  33. 7.6.2 Mylan Business Overview
  34. 7.6.3 Mylan Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Mylan Coccidioidomycosis Drug Product Portfolio
  36. 7.6.5 Mylan Recent Developments
  37. 7.7 Lunan Pharmaceutical
  38. 7.7.1 Lunan Pharmaceutical Company Information
  39. 7.7.2 Lunan Pharmaceutical Business Overview
  40. 7.7.3 Lunan Pharmaceutical Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Lunan Pharmaceutical Coccidioidomycosis Drug Product Portfolio
  42. 7.7.5 Lunan Pharmaceutical Recent Developments
  43. 7.8 Kelun
  44. 7.8.1 Kelun Company Information
  45. 7.8.2 Kelun Business Overview
  46. 7.8.3 Kelun Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Kelun Coccidioidomycosis Drug Product Portfolio
  48. 7.8.5 Kelun Recent Developments
  49. 7.9 Pfizer
  50. 7.9.1 Pfizer Company Information
  51. 7.9.2 Pfizer Business Overview
  52. 7.9.3 Pfizer Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Pfizer Coccidioidomycosis Drug Product Portfolio
  54. 7.9.5 Pfizer Recent Developments
  55. 7.10 Bayer
  56. 7.10.1 Bayer Company Information
  57. 7.10.2 Bayer Business Overview
  58. 7.10.3 Bayer Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Bayer Coccidioidomycosis Drug Product Portfolio
  60. 7.10.5 Bayer Recent Developments
  61. 7.11 Baxter
  62. 7.11.1 Baxter Company Information
  63. 7.11.2 Baxter Business Overview
  64. 7.11.3 Baxter Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Baxter Coccidioidomycosis Drug Product Portfolio
  66. 7.11.5 Baxter Recent Developments
  67. 7.12 Sanofi-Aventis
  68. 7.12.1 Sanofi-Aventis Company Information
  69. 7.12.2 Sanofi-Aventis Business Overview
  70. 7.12.3 Sanofi-Aventis Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Sanofi-Aventis Coccidioidomycosis Drug Product Portfolio
  72. 7.12.5 Sanofi-Aventis Recent Developments
  73. 7.13 Hexal
  74. 7.13.1 Hexal Company Information
  75. 7.13.2 Hexal Business Overview
  76. 7.13.3 Hexal Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Hexal Coccidioidomycosis Drug Product Portfolio
  78. 7.13.5 Hexal Recent Developments
  79. 7.14 Apotex
  80. 7.14.1 Apotex Company Information
  81. 7.14.2 Apotex Business Overview
  82. 7.14.3 Apotex Coccidioidomycosis Drug Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Apotex Coccidioidomycosis Drug Product Portfolio
  84. 7.14.5 Apotex Recent Developments
8 North America
  1. 8.1 North America Coccidioidomycosis Drug Revenue (2021-2032)
  2. 8.2 North America Coccidioidomycosis Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Coccidioidomycosis Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Coccidioidomycosis Drug Revenue by Type (2027-2032)
  5. 8.3 North America Coccidioidomycosis Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Coccidioidomycosis Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Coccidioidomycosis Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Coccidioidomycosis Drug Revenue by Application (2027-2032)
  9. 8.5 North America Coccidioidomycosis Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Coccidioidomycosis Drug Revenue by Country
  11. 8.6.1 North America Coccidioidomycosis Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Coccidioidomycosis Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Coccidioidomycosis Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Coccidioidomycosis Drug Revenue (2021-2032)
  2. 9.2 Europe Coccidioidomycosis Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Coccidioidomycosis Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Coccidioidomycosis Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Coccidioidomycosis Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Coccidioidomycosis Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Coccidioidomycosis Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Coccidioidomycosis Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Coccidioidomycosis Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Coccidioidomycosis Drug Revenue by Country
  11. 9.6.1 Europe Coccidioidomycosis Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Coccidioidomycosis Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Coccidioidomycosis Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Coccidioidomycosis Drug Revenue (2021-2032)
  2. 10.2 China Coccidioidomycosis Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Coccidioidomycosis Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Coccidioidomycosis Drug Revenue by Type (2027-2032)
  5. 10.3 China Coccidioidomycosis Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Coccidioidomycosis Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Coccidioidomycosis Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Coccidioidomycosis Drug Revenue by Application (2027-2032)
  9. 10.5 China Coccidioidomycosis Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Coccidioidomycosis Drug Revenue (2021-2032)
  2. 11.2 Asia Coccidioidomycosis Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Coccidioidomycosis Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Coccidioidomycosis Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Coccidioidomycosis Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Coccidioidomycosis Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Coccidioidomycosis Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Coccidioidomycosis Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Coccidioidomycosis Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Coccidioidomycosis Drug Revenue by Country
  11. 11.6.1 Asia Coccidioidomycosis Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Coccidioidomycosis Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Coccidioidomycosis Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Coccidioidomycosis Drug Revenue (2021-2032)
  2. 12.2 SAMEA Coccidioidomycosis Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Coccidioidomycosis Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Coccidioidomycosis Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Coccidioidomycosis Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Coccidioidomycosis Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Coccidioidomycosis Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Coccidioidomycosis Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Coccidioidomycosis Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Coccidioidomycosis Drug Revenue by Country
  11. 12.6.1 SAMEA Coccidioidomycosis Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Coccidioidomycosis Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Coccidioidomycosis Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst